J Clin Lipidol. May - Jun 2017;11(3):624-637. PMID: 28506385. 64. Suzuki H, Watanabe Y, Kumagai H, Shuto H. Comparative efficacy and adverse effects of the addition of ezetimibe to statin versus statin titration in chronic kidney disease patients. Ther Adv Cardiovasc Dis. Dec 2013;7(6):306-315. PMID: 24280596. 65. Mikhailidis DP, Lawson RW, McCormick AL, et al. Comparative efficacy of the addition of ezetimibe to statin vs statin titration in patients with hypercholesterolaemia: Systematic review and meta-analysis. Curr Med Res Opin. Jun 2011;27(6):1191-1210. PMID: 21473671. 66. Baigent C, Landray MJ, Reith C, et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): A randomised placebo- controlled trial. Lancet. Jun 25 2011;377(9784):2181-2192. PMID: 21663949. 67. Cannon CP, Blazing MA, Giugliano RP, et al. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med. Jun 18 2015;372(25):2387-2397. PMID: 26039521. 68. Du H, Li X, Su N, et al. Proprotein convertase subtilisin/kexin 9 inhibitors in reducing cardiovascular outcomes: A systematic review and meta-analysis. Heart. Aug 2019;105(15):1149-1159. PMID: 30842207. 69. Robinson JG, Farnier M, Krempf M, et al. Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. N Engl J Med. Apr 16 2015;372(16):1489-1499. PMID: 25773378. 70. Schmidt AF, Pearce LS, Wilkins JT, Overington JP, Hingorani AD, Casas JP. PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease. Cochrane Database Syst Rev. Apr 28 2017; 4:CD011748. PMID: 28453187. 71. Korman MJ, Retterstol K, Kristiansen IS, Wisloff T. Are PCSK9 inhibitors cost effective? Pharmacoeconomics. Sep 2018;36(9):1031-1041. PMID: 29777433. 72. Kazi DS, Penko J, Coxson PG, Guzman D, Wei PC, Bibbins-Domingo K. Cost-effectiveness of alirocumab: A just-in-time analysis based on the ODYSSEY outcomes trial. Ann Intern Med. Jan 1 2019. PMID: 30597485. 73. 